top of page
25 Jul 2023
Afferent Medical Solutions announces a successful completion of its Phase II sham-controlled randomized trial, looking at autonomic modulation by transcutaneous vagal nerve stimulation in acute ischemic stroke patients requiring mechanical thrombectomy
Afferent Medical Solutions announces a successful completion of its Phase II sham-controlled randomized trial, looking at autonomic modulation by transcutaneous vagal nerve stimulation in acute ischemic stroke patients requiring mechanical thrombectomy
bottom of page